Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

Findings showed both zanidatamab treatment arms demonstrated statistically significant and clinically meaningful improvements in PFS vs the SOC arm.

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced that the first patient has been dosed in its ...

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

The Realme GT 8 Pro is equipped with one of highest-specced displays in the lineup, and in the sister brands' lineups too.

The therapeutic landscape for hepatocellular carcinoma (HCC) has been revolutionized by the advent of molecular targeted therapies and immune ...

"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

Claims about its benefits extend far beyond helping people to stay calm and range from boosting heart health to immunity, ...